echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > For the first time covering two major types of heart failure SGLT2 inhibitors, another breakthrough

    For the first time covering two major types of heart failure SGLT2 inhibitors, another breakthrough

    • Last Update: 2021-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Lilly and Boehringer Ingelheim jointly announced that the SGLT2 inhibitor Jardiance (empagliflozin, empagliflozin) is in a phase 3 clinical trial for the treatment of patients with preserved ejection fraction heart failure (HFpEF) Reaching the primary endpoint significantly reduces the composite risk of cardiovascular death or hospitalization for heart failure in adult patients (with or without diabetes)


    The press release states that this is the first SGLT2 inhibitor to significantly reduce the risk of cardiovascular death or heart failure hospitalization in this patient group


    There are more than 60 million heart failure patients worldwide, and half of them suffer from HFpEF


    Although patients with HFrEF have ushered in a variety of innovative therapies in recent years, there has been no FDA-approved therapy for HFpEF for many years, until Novartis' Entresto (sakubatril/valsartan, Chinese brand name Nuoxinto) was awarded in February this year.


    Enpagliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor.


    In June of this year, it was approved by the European Commission for the treatment of patients with HFrEF


    The phase 3 clinical trial called EMPEROR-Preserved included 5988 HFpEF patients.


    SGLT2 inhibitors were originally used as hypoglycemic therapy to treat patients with type 2 diabetes.


    Note: The original text has been deleted

    Reference materials:

    [1] Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction.


    [2] What's the Difference Between Systolic and Diastolic Heart Failure? Retrieved July 6, 2021, from https://

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.